Гепарин

Quick links to important sections

Гепарин

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Гепарин

Quick Facts

  • Class: Anticoagulant (often called a “blood thinner”)
  • Mechanism: Enhances the activity of antithrombin, which inactivates key clotting factors.
  • Administration: Given by injection (intravenous or subcutaneous) because it is not absorbed orally.

Heparin is a medication classified as an anticoagulant, or a drug used to prevent the formation of blood clots (thrombi) or to prevent existing clots from growing larger. While often called a “blood thinner,” it does not actually thin the blood; instead, it prolongs the time it takes for blood to clot.

Mechanism of Action

Heparin works by binding to a natural enzyme inhibitor in the blood called antithrombin (AT). This binding causes a conformational change in antithrombin, which significantly increases its ability to inactivate several crucial coagulation (clotting) factors, particularly thrombin (Factor IIa) and Factor Xa. By inactivating these factors, heparin disrupts the coagulation cascade, preventing the conversion of fibrinogen to fibrin, which is the final step in creating a stable clot.

Types and Uses

Heparin is available in several forms, most commonly as Unfractionated Heparin (UFH) and Low-Molecular-Weight Heparins (LMWHs). Healthcare providers use heparin to treat or prevent blood clot conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial embolisms. It is also used during certain medical procedures, including open-heart surgery, bypass surgery, and dialysis, to prevent clotting in the circulatory system or medical equipment. LMWHs, such as enoxaparin, have a longer half-life and more predictable effect than UFH, allowing for less frequent dosing and typically not requiring the same level of routine lab monitoring.

What side effects are possible with Гепарин?

Possible Side Effects and Safety Information

The official safety information for Heparin is structured around its classification as an anticoagulant, with the primary and most frequently documented adverse effect being hemorrhage (bleeding). This risk is commonly observed, though its severity is dose-dependent and necessitates careful consideration, as noted in regulatory labeling from authorities like the FDA and EMA.

Frequency and Systemic Effects

Adverse reactions are classified by frequency, with elevated liver enzymes (transaminases) being documented as very common, though often transient. Effects on the Blood and Lymphatic System Disorders also include thrombocytopenia (a decrease in platelets), which is generally common but mild (Type I).

Serious Adverse Reactions

The label details several serious adverse reactions. These include Major Hemorrhage and the rare, immune-mediated complication known as Heparin-Induced Thrombocytopenia (HIT) Type II, which presents a paradoxical risk of new clot formation. Additionally, the risk of spinal or epidural hematoma is a documented serious concern, particularly when Heparin use coincides with neuraxial procedures. Severe hypersensitivity reactions (anaphylaxis) are also listed.

Population-Specific and Duration-Related Safety

Safety statements note that specific populations, such as older adults and patients with severe renal impairment, may have an increased risk of hemorrhage due to altered drug clearance. Regarding exposure, osteoporosis and alopecia (hair loss) are documented as risks associated with prolonged, long-term administration (typically several months of use).

Overdose and Emergency Response

Overdose and when to seek help

Overdosage with Heparin is defined by the exaggeration of its anticoagulant effect, resulting in hemorrhage or bleeding, which is the principal clinical manifestation documented in regulatory sources. Specific presentations of overdosage include signs of blood loss such as epistaxis (nosebleeds), hematuria (blood in the urine), easy bruising, and melena (tarry stools). Laboratory findings consistent with overdosage include a prolongation of the activated Partial Thromboplastin Time (aPTT).

Overdosage carries the official risk of major bleeding events and has been associated with fatal hemorrhages. Immediate medical attention and treatment is required if any signs of unusual bleeding or an unexplained fall in blood pressure or hematocrit are observed.

Management protocols, as described in regulatory labeling, are structured around specific interventions:

  • Antidote: The specific neutralizing agent is Protamine sulfate, which is administered intravenously under strict medical supervision to reverse the anticoagulant effect.
  • Supportive Measures: Discontinuation of the drug is required. Management involves close observation, monitoring the aPTT, and may necessitate blood or plasma transfusions in severe cases.

Therapeutic Uses of Гепарин

What Heparin Treats: Main Uses and Benefits

Heparin is an important anticoagulant (blood thinner) that is commonly used to help with reducing the formation of new blood clots and plays a role in managing the progression of existing clots. Its main therapeutic domain involves managing and preventing conditions characterized by periods of heightened symptoms related to blood clots. The benefits center on providing support that helps ease the overall symptom burden associated with periods of heightened systemic burden.

Main indications include the prophylaxis and treatment of venous thromboembolism (VTE), which encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as thromboembolic complications associated with heart rhythm issues like atrial fibrillation with embolization. This medicine is commonly used to help with managing clotting during specialized clinical scenarios, such as open-heart surgery, arterial surgery, kidney dialysis procedures, and blood transfusions, where it assists with maintaining functional stability.

Quick Fact: Relief for Symptoms related to heightened physiological activity

Eligibility and Restrictions for Use

The eligibility profile for Heparin is strictly defined by regulatory documentation and centers on pre-existing conditions that increase the risk of hemorrhage. The medicine is contraindicated in patients with an established history of Heparin-Induced Thrombocytopenia (HIT) or HIT with Thrombosis (HITT). Absolute non-eligibility also applies to individuals with an uncontrollable active bleeding state or severe thrombocytopenia.

Use of the medicine is restricted or requires heightened caution in several specific populations. Patients over 60 years of age, particularly women, have a higher documented incidence of bleeding and may require special consideration. Coexisting conditions like severe hypertension, subacute bacterial endocarditis, or severe liver disease limit eligibility due to increased risk.

For age-related restrictions, neonates and infants must only be administered a preservative-free formulation due to regulatory warnings about benzyl alcohol toxicity. Similarly, use during pregnancy and lactation is generally permitted but requires the preservative-free product, as documented in official labeling. Standard use is established for adults, and use in the pediatric population is based on clinical experience.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines Heparin's interaction profile primarily through pharmacodynamic reinforcement, where co-administration with specific drug classes results in an additive effect on the hemostatic system, escalating the risk of hemorrhage. The use of Platelet Aggregation Inhibitors (such as NSAIDs and acetylsalicylic acid) and other Anticoagulants (including Warfarin, Factor Xa inhibitors, and Direct Thrombin Inhibitors) is officially documented to potentiate bleeding risk.


Documented Interaction Categories

  • Pharmacodynamic Hemostatic Reinforcement: Combination with Thrombolytic Agents (e.g., Alteplase) or certain systemic Glucocorticoids significantly reinforces the risk of severe bleeding complications.
  • Exposure-Altering Co-administration: Intravenous co-administration of Glyceryl Trinitrate (Nitroglycerin) is officially documented to decrease the measurable anticoagulant effect of Heparin, potentially necessitating closer monitoring.
  • Herbal/Supplement Cautions: Certain herbal products (e.g., Gingko biloba, Garlic, high-dose Vitamin E) are officially noted to possess anti-clotting properties that may contribute to the overall anti-hemostatic burden.

Population-Specific Notes

The interaction profile for Low-Molecular-Weight Heparins (LMWHs) includes an official caution for patients with severe renal impairment. Reduced clearance in this population leads to increased exposure of the LMWH, thereby heightening the potential for pharmacodynamic interactions and bleeding events.

Mechanism of Action

How Гепарин Works

Гепарин produces its effect by modulating the blood coagulation system, acting as a highly specific catalyst for the body's natural clotting inhibitor system. Its mechanism focuses on enhancing the function of existing proteins within the blood plasma to rapidly suppress key enzymatic reactions.

Boosting the Natural Inhibitor Antithrombin

Гепарин's primary biological target is the protein Antithrombin (AT). The drug binds to AT, causing a change in its molecular shape that greatly accelerates its capacity to neutralize activated clotting enzymes. This enhancement of the blood's intrinsic inhibitory capacity facilitates a decreased rate of coagulation.

Inhibiting the Coagulation Cascade

This interaction results in the rapid inactivation of key coagulation factors, specifically Factor Xa and Thrombin (Factor IIa). The Гепарин-AT complex functions as a template, rapidly trapping and blocking the active sites of these enzymes. By neutralizing Thrombin, the drug prevents the conversion of fibrinogen to fibrin, which results in a reduction of the blood's capacity to form or extend stable clots.

Dosage and Administration Information

How to Use Heparin (Гепарин) – Administration Guidelines

Heparin is administered exclusively by parenteral routes, meaning by injection or infusion, as it is not absorbed orally. The standard methods include Intravenous (IV) infusion, Intermittent IV injection, and deep Subcutaneous (SC) injection. Intramuscular (IM) injection is strictly avoided due to the high risk of forming a large hematoma at the injection site.


Dosing and Administration Schedules

The required dose and frequency are not fixed but depend entirely on the clinical indication and require laboratory monitoring of blood clotting times. The most critical aspect of therapeutic use is dose titration based on the Activated Partial Thromboplastin Time (aPTT) to achieve a desired therapeutic range.

Usage Scenario Typical Regimen (Adults) Frequency Pattern
Therapeutic Treatment Initial IV Bolus of 5,000–10,000 units, followed by a maintenance Continuous IV Infusion (e.g., 20,000–40,000 units per 24 hours). Highly frequent (continuous or divided doses every 4–12 hours).
Prophylaxis (Prevention) 5,000 units via SC injection. Administered typically every 8 or 12 hours.

Procedural and Population Rules

For continuous IV administration, the concentrated solution must be diluted in a compatible IV fluid and thoroughly mixed prior to infusion. Subcutaneous injections should be administered into the abdominal fat layer, and a different site must be used for each injection.

Dosage may require modification in certain populations. Pediatric patients, particularly neonates and infants, require specific weight-based loading and maintenance doses; only preservative-free Heparin formulations must be used for this group. Older adults may require dose reduction due to potentially altered response to the medication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Гепарин (Heparin)


Evidence for Treating Acute Blood Clots (Venous Thromboembolism or VTE)

Research into using Heparin to manage existing blood clots, such as Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), primarily involves randomized controlled trials (RCTs) and systematic reviews. These studies were studied for how they were studied for managing existing clots in conditions involving periods of heightened symptoms related to clotting. The studies monitored several key outcomes reflecting daily functioning or activity level, which included tracking VTE recurrence and all-cause mortality during the observed time interval.

Comparative trials examined the measured rates of VTE recurrence and tracked patient readmissions associated with clotting events. Research highlights changes measured during the study period for these outcomes, often involving acutely ill, hospitalized adult populations.


Evidence for Preventing Blood Clots (VTE Prophylaxis)

To prevent blood clots (prophylaxis), evidence comes from multiple randomized controlled trials and subsequent meta-analyses. These studies research examined its role in high-risk settings, specifically in adult patients undergoing major surgery and in medically ill patients with reduced mobility. The main outcomes describing episodic or acute changes that were monitored included tracking the measured incidence of symptomatic and asymptomatic DVT and PE. Studies report patterns of VTE incidence observed in the populations, comparing those who received Heparin to those who received other or no anticoagulation.


Evidence in Special Populations and Research Gaps

Research studies explored Heparin use in patient groups outside the general adult population, though evidence quality varies across studies. For example, in older adults and those with certain comorbid conditions, data show patterns related to VTE recurrence similar to the general population. However, for children or pregnant individuals, data for certain groups remain insufficient due to smaller study sizes. Long-term studies are less common, and long-term effects are not fully established regarding whether initial use influences later outcomes related to systemic or functional imbalance years after the initial intervention. Findings were mixed when comparing different forms of Heparin for specific outcomes, and certainty remains low for some complex subgroups, meaning research is ongoing in these areas.

Key Studies & References

  1. Low Dose Low-Molecular-Weight Heparin for Thrombosis Prophylaxis: Systematic Review with Meta-Analysis and Trial Sequential Analysis
  2. Heparin - StatPearls (Review of Indications including Extracorporeal Circulation)

Frequently Asked Questions (FAQ)

Common questions about Гепарин (FAQ)


Q: Is Heparin really used during pregnancy?

Official labeling indicates that unfractionated heparin does not cross the placenta due to its large molecular weight. Its use during pregnancy is described as acceptable, with official guidance noting that a preservative-free formulation is typically used.


Q: How quickly does Heparin start working after administration?

After intravenous (IV) injection, the anticoagulant effect is considered immediate. Its elimination half-life is relatively short, often cited as being between 30 minutes to 2 hours. This time frame can be variable.


Q: Can Heparin be used if I have liver problems?

Severe liver disease is listed in official documents as a condition that requires heightened caution or may be considered a contraindication due to an increased risk of bleeding. In cases of advanced disease, official information suggests that dosage may require modification or reduction.


Q: How does Heparin affect wound healing?

Heparin's primary documented safety concern is hemorrhage (bleeding). Reflecting this risk, official information states the drug is contraindicated in patients with an active bleeding state or immediately following certain types of surgery. This indicates the concern that its effect may interfere with the necessary clotting process required for wound closure. If there is concern about a reaction, consulting a healthcare provider is generally indicated.


Q: What should I do if a lump appeared after a Heparin injection?

Official documents list potential local reactions at the injection site, including pain, irritation, redness, and hematoma (a collection of blood that can feel like a lump). Skin necrosis, a rare but serious side effect, is also listed and may begin with painful, red lesions. If there is concern about a reaction, consulting a healthcare provider is generally indicated.


Q: How long does Heparin stay in the body?

The elimination half-life for unfractionated heparin, particularly when given intravenously, is relatively short. Official pharmacokinetic information often cites this half-life as being between 30 minutes and 2 hours, though this rate can be highly variable depending on the patient.


Q: What is 'low-molecular-weight heparin' and is it the same thing?

Low-Molecular-Weight Heparin (LMWH) is a chemically modified form of heparin where the molecular chains are made shorter. Official information indicates LMWH has a longer and more predictable activity in the body and does not typically require the same level of regular blood monitoring as unfractionated heparin.


Q: Do I need to change anything in my diet when taking Heparin?

Official drug information notes high alcohol consumption as a potential interaction point that requires caution. However, no specific food or general dietary restrictions are documented in the main prescribing information for unfractionated heparin.


Q: What should be done if a dose of Heparin is missed (informational only)?

Patient information generally describes a procedure where a missed dose is taken as soon as possible, unless it is close to the time for the next scheduled dose. In that scenario, the instruction is to skip the missed dose. It is explicitly stated in patient documents not to take a double or extra dose to make up for the missed one.


Q: Is Heparin used in the form of an ointment or only injections?

Unfractionated Heparin is officially administered by injection or infusion because regulatory information states it is poorly absorbed orally. However, regulatory agencies in some regions have approved and documented the use of related compounds, such as heparinoid creams, for topical uses associated with dry skin or localized swelling.


Q: Can Heparin affect blood pressure?

Official warnings list that Heparin should be used with extreme caution in patients with uncontrolled or severe hypertension due to the increased risk of hemorrhage. Adverse event reports have also included instances of hypotension (low blood pressure) associated with hypersensitivity reactions.


Q: Why must Heparin injections be given under the skin and not into the muscle?

Intramuscular (IM) injection is explicitly prohibited or contraindicated by regulatory guidelines. Official sources state that this route carries a high risk of causing a large hematoma (serious localized bleeding) at the injection site.


Q: Are there known interactions between Heparin and alcohol?

High alcohol consumption is officially listed as a condition that requires caution or may be considered a contraindication. This is due to the potential for excessive alcohol use to predispose the patient to hemorrhage (serious bleeding) during Heparin administration.


Q: What is known about the use of Heparin in children?

Use in the pediatric population is established. Regulatory guidelines note that neonates and infants require specific weight-based dosing. Official guidance indicates they are only to be administered a preservative-free formulation due to the risk of benzyl alcohol toxicity in this age group.


Q: What is the antidote for Heparin?

Protamine sulfate is the medicine documented in official literature and regulatory dosing information as the counteracting agent used to neutralize or reverse the anticoagulant effects of Heparin. This counteracting agent is generally used in cases of severe bleeding or documented overdose.


Q: Why isn't Heparin sold in pill form?

Heparin is not available in oral (pill) form because it is a large, highly charged molecule. Official drug information indicates that it is poorly absorbed in the gastrointestinal tract and is rapidly metabolized. Therefore, it must be administered by injection or infusion to be effective.


Q: Does Heparin affect the menstrual cycle?

Official adverse reaction documents list increased menstrual flow or unusually heavy vaginal bleeding as a less common side effect. The general risk of bleeding associated with the drug may also exacerbate existing menstrual flow or lead to changes in its regularity.


Q: What is a 'Heparin Lock'?

A Heparin Lock Flush Solution is an officially listed and regulated product. It is a very low-dose solution used specifically as an anticoagulant to maintain the patency (openness) of an intravenous catheter or vascular access line, preventing it from clotting between uses.


Q: What should I do if I accidentally froze the Heparin?

Storage guidelines mandate that Heparin must be protected from freezing. Official guidance suggests that freezing can cause a loss of potency, that its effectiveness may be compromised, and that the product should be discarded.


Q: What is known about Heparin use during breastfeeding?

Official sources state that any form of Heparin (UFH or LMWH) can be used during breastfeeding. Due to its large molecular weight, it is expected to pass into breast milk in negligible amounts and is not expected to be absorbed by the breastfed infant.


Q: How is Heparin different from Aspirin?

Heparin is an anticoagulant that works by enhancing the action of antithrombin to directly inactivate key clotting factors. Aspirin, which is mentioned in the interactions section, is officially described as a Platelet Aggregation Inhibitor. This indicates the two drugs interfere with the body's clotting ability through different biological mechanisms.

How should Гепарин be stored and disposed of?

How to Store and Dispose of Heparin

Heparin must be stored under specific conditions mandated by regulatory labeling to maintain its potency.


Storage and Stability

Heparin Sodium Injection is typically required to be stored at controlled room temperature (20 C to 25 C / 68 F to 77 F). The product must be protected from freezing, as this can cause a loss of potency.

Before use, the solution must be visually inspected; if it contains particulate matter or is discolored, it must be discarded. Multi-dose vials must be discarded 28 days after the date of first puncture. Single-dose units must be discarded immediately after use.


Handling and Disposal

Heparin must be kept out of the reach and sight of children. Unused or expired medication must be disposed of according to local regulatory requirements for medicinal products and must not be thrown away in household waste or flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Гепарин found in:

A-Z Index: